To the Editor,
The manuscript by Drs. Moreno-Campoy et al. [1] described the usage of tumor markers (TMs) in a retrospective cohort of 14,728 patients over a 2-year period (2011) (2012) (2013) at the University Hospital of Padua. The authors assert that only 40% of TM requests are appropriate, increasing patient anxiety and the risk of patient harm through unnecessary complementary tests. While we applaud the authors for the effort to summarize and provide an overview on the number of selected TMs ordered at a large urban hospital, we feel some comments are warranted with regards to the authors' analysis and interpretation of their study results. [2] , the use of PSA is still recommended in select populations for prostate cancer screening [3] , it is prognostic in localized disease and after initiation of hormone-ablative treatment for advanced cancer, and it can be used for treatment monitoring or active surveillance [4] . Given that prostate and liver cancer accounted for over 50,000 cancer diagnoses in Italy in 2012 [5] , excluding orders for disease monitoring with these two commonly used TMs (all of which would be 'appropriate' by the authors' definition) fails to capture a large number of appropriate and noncontroversial TM uses. 2. Characterizing the use of group 1 TMs prior to pathologic diagnosis of cancer as 'inappropriate' fails to consider uses recommended by guidelines and also based on published data in large cohorts for the differential diagnosis of a pelvic mass [6] CEA in the work-up of suspected colorectal carcinoma [7] , and appropriate work-up and triage of suspicious pulmonary nodules [8] . These examples are all indications done in individuals without a diagnosis of malignancy. In addition, a TM such as CA 125 is more sensitive for peritoneal carcinomatosis than most imaging modalities. It might also be ordered to detect micrometastatic omental spread of a gastrointestinal malignancy [9] . In this case, a negative result is not an inappropriate test, but informative and useful for the further treatment planning of the patient. 3. The authors note that in over 26% of cases, four or more TMs are ordered, suggesting inappropriate usage of the group 1 TMs for screening of undiagnosed tumors. However, the number of multiple TMs determined for a single patient reflects the actual biology of these markers as also conceded by the authors in the introduction: none have 100% sensitivity. Thus, for a given condition (e.g. gastric carcinoma), no single TM will cover all patients, whereas a combination, e.g. CEA, CA 19-9, cancer antigen 72-4 (CA 72-4), CA 15-3, and CA 125, might identify a higher proportion of patients with at least one elevated TM which can then be followed [10] . While it has become fashionable to dismiss traditional TMs, we believe few other diagnostic tools are as inexpensive, easy to obtain, and as safe to use. We disagree with the authors' conclusion that protocols for the safe use of TMs are needed, as we are unaware of any data demonstrating that their current usage is unsafe. Rather, what is needed is better education and familiarization of physicians with the correct use and interpretation of TMs so that their value as an additional tool in the diagnostic armamentarium can be improved. The crude classification of appropriateness of TM ordering based on non-granular groups 1 and 2 is akin to assuming most drivers on a busy highway are lost just because one does not know their actual destination.
